Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$28.75 -0.9%	$30.12	$22.90 ▼ $36.45	$4.76B	0.44	1.74 million shs	1.12 million shs
FGEN FibroGen	$5.69 +8.4%	$7.16	$4.50 ▼ $38.25	$22.67M	0.74	75,779 shs	33,072 shs
INSM Insmed	$98.50 +0.3%	$80.87	$60.40 ▼ $106.83	$18.55B	0.9	2.30 million shs	1.76 million shs
LEGN Legend Biotech	$35.35 -1.6%	$32.56	$27.34 ▼ $60.87	$6.55B	0.19	1.37 million shs	604,100 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-0.21%	-8.85%	-4.36%	+18.65%
FGEN FibroGen	0.00%	+9.00%	-25.40%	-18.71%	-67.06%
INSM Insmed	0.00%	-1.00%	+33.67%	+42.38%	+58.87%
LEGN Legend Biotech	0.00%	+2.08%	+16.44%	+10.43%	-23.00%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	+4.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.9367 of 5 stars	4.4	3.0	0.0	4.2	3.4	2.5	1.9
FGEN FibroGen	4.7157 of 5 stars	3.3	3.0	0.0	4.7	4.4	3.3	0.6
INSM Insmed	4.1548 of 5 stars	2.5	4.0	0.0	4.3	3.5	1.7	0.6
LEGN Legend Biotech	3.1189 of 5 stars	4.5	1.0	0.0	0.0	2.6	1.7	0.6
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.83	Moderate Buy	$40.00	39.13% Upside
FGEN FibroGen	2.50	Moderate Buy	$250.00	4,293.67% Upside
INSM Insmed	3.00	Buy	$106.80	8.43% Upside
LEGN Legend Biotech	2.91	Moderate Buy	$72.60	105.37% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest FGEN, ALKS, INSM, LEGN, and MOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$60.00 ➝ $54.00
6/17/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$33.00 ➝ $42.00
6/11/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $112.00
6/11/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
6/11/2025	INSM Insmed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$99.00 ➝ $106.00
6/11/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $102.00
6/11/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$107.00 ➝ $119.00
6/11/2025	INSM Insmed	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$94.00 ➝ $109.00
6/11/2025	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$90.00 ➝ $120.00
6/10/2025	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/10/2025	INSM Insmed	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.56B	3.04	$2.64 per share	10.88	$9.05 per share	3.18
FGEN FibroGen	$29.62M	0.78	N/A	N/A	($50.89) per share	-0.11
INSM Insmed	$363.71M	51.38	N/A	N/A	$1.60 per share	61.56
LEGN Legend Biotech	$627.24M	10.36	N/A	N/A	$5.70 per share	6.20
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.09	13.76	20.99	1.79	23.30%	27.52%	17.98%	7/23/2025 (Estimated)
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/5/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
LEGN Legend Biotech	-$177.03M	-$0.59	0.00	N/A	N/A	-29.95%	-21.19%	-13.47%	8/8/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A

Latest FGEN, ALKS, INSM, LEGN, and MOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	ALKS Alkermes	$0.42	N/A	N/A	N/A	$343.20 million	N/A
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.33	2.92
FGEN FibroGen	N/A	2.02	1.98
INSM Insmed	11.38	5.86	5.44
LEGN Legend Biotech	0.30	5.20	5.07
MOR MorphoSys	4.98	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
FGEN FibroGen	72.71%
INSM Insmed	N/A
LEGN Legend Biotech	70.89%
MOR MorphoSys	18.38%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
FGEN FibroGen	3.07%
INSM Insmed	3.00%
LEGN Legend Biotech	0.02%
MOR MorphoSys	0.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	1,800	164.90 million	157.65 million	Optionable
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable

FGEN, ALKS, INSM, LEGN, and MOR Headlines

Recent News About These Companies

2seventy bio (NASDAQ:TSVT) and MorphoSys (NASDAQ:MOR) Critical Comparison

July 4 at 2:25 AM | americanbankingnews.com

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer

June 17, 2025 | finance.yahoo.com

Essential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsight

March 21, 2025 | theglobeandmail.com

Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts

February 12, 2025 | seekingalpha.com

VIDEO: Triplet therapy improved PFS in relapsed, refractory follicular lymphoma

January 15, 2025 | healio.comH

Novartis closing Morphosys facilities, laying off 330 workers

January 8, 2025 | bioworld.comB

Swiss pharma giant Novartis to close biotech firm Morphosys

December 20, 2024 | swissinfo.chS

Novartis to shut MorphSys sites amid pelabresib delay

December 20, 2024 | thepharmaletter.comT

Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs

December 19, 2024 | biospace.comB

Novartis sheds MorphoSys staff, sites after pelabresib delay

December 19, 2024 | pharmaphorum.comP

Novartis shutters MorphoSys sites, lays off staff

December 19, 2024 | finance.yahoo.com

Some 330 jobs hit as Novartis closes Morphosys, WiWo reports

December 19, 2024 | reuters.com

Novartis raises mid-term sales guidance

November 21, 2024 | seekingalpha.com

Novartis: launch of Morphosys drug by could be 2027 or later

November 21, 2024 | reuters.com

Idiopathic Membranous Nephropathy Market Size is estimated to grow with a significant CAGR during the study period (2020-2034).

November 14, 2024 | theglobeandmail.com

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

November 12, 2024 | manilatimes.netM

Moderna said to shuffle sales leadership; Vertex records first Casgevy sale

November 6, 2024 | biopharmadive.comB

Tango stock plunges 28% amid pipeline updates, Q3 earnings report

November 6, 2024 | msn.com

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug

November 1, 2024 | biopharmadive.comB

Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Office

October 31, 2024 | pharmiweb.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
By Gabriel Osorio-Mazilli | June 16, 2025
View China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
Russell Rebalance: 3 Stocks Ready to Move Higher
By Chris Markoch | June 20, 2025
View Russell Rebalance: 3 Stocks Ready to Move Higher
Tariff Talks Advance, What Taiwan Semiconductor Can Deliver
By Gabriel Osorio-Mazilli | June 16, 2025
View Tariff Talks Advance, What Taiwan Semiconductor Can Deliver

FGEN, ALKS, INSM, LEGN, and MOR Company Descriptions

Alkermes NASDAQ:ALKS

$28.75 -0.25 (-0.86%)

Closing price 07/3/2025 03:26 PM Eastern

Extended Trading

$28.75 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

FibroGen NASDAQ:FGEN

$5.69 +0.44 (+8.38%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$5.61 -0.08 (-1.41%)

As of 07/3/2025 04:56 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Insmed NASDAQ:INSM

$98.50 +0.26 (+0.26%)

Closing price 07/3/2025 03:07 PM Eastern

Extended Trading

$98.50 0.00 (0.00%)

As of 07/3/2025 04:34 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Legend Biotech NASDAQ:LEGN

$35.35 -0.56 (-1.56%)

Closing price 07/3/2025 02:47 PM Eastern

Extended Trading

$35.35 0.00 (0.00%)

As of 07/3/2025 04:48 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 07/3/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time